[City, State] – [Date] – Soligenix, Inc., a clinical-stage biopharmaceutical company, has announced a significant strategic redirection following the termination of its late-stage development program for HyBryte, a topical therapy intended for cutaneous T-cell lymphoma (CTCL). The decision stems from interim analysis of the Phase III FLASH2 trial, which indicated that HyBryte was unlikely to achieve its primary endpoints. Consequently, Soligenix will now concentrate its efforts on advancing its rare disease pipeline candidate, dusquetide, and further developing its innovative ambient-stable vaccine platform, ThermoVax.
This pivot marks a critical juncture for Soligenix, signaling a move away from a promising, albeit ultimately unsuccessful, venture in CTCL treatment. The company’s leadership has emphasized a renewed commitment to areas where they believe significant unmet needs and commercial opportunities exist.
The HyBryte Endeavor: A Novel Approach to CTCL Treatment
HyBryte, formerly known by its development codes SGX301 or synthetic hypericin sodium, represented a novel therapeutic strategy for CTCL. The topical gel was designed to be activated by visible light within the red-yellow spectrum. The underlying hypothesis was that malignant T-cells, which selectively absorb this light, would be targeted and destroyed when exposed to the activated hypericin. This approach aimed to selectively eliminate diseased cells without causing collateral damage to healthy cellular DNA, a significant concern in oncological therapies.
Cutaneous T-cell lymphoma (CTCL) is a rare and often debilitating form of non-Hodgkin lymphoma that primarily affects the skin. In its early stages, CTCL can manifest as red, itchy patches, and is often managed with topical treatments and phototherapy. However, for patients with more advanced disease, treatment options become more aggressive, including stem cell transplants, targeted therapies, and chemotherapy. The development of HyBryte was intended to offer a less invasive and potentially more targeted option for a significant patient population.
Setbacks in the FLASH2 Trial: A Disappointing Outcome
The development of HyBryte faced a significant hurdle with the interim analysis of the Phase III FLASH2 trial (NCT06470451). Conducted by an independent data monitoring committee, the analysis in May 2026 revealed that the trial was statistically unlikely to meet its primary efficacy endpoints. This finding prompted Soligenix to re-evaluate the program’s viability.
Following a comprehensive assessment of the interim data and the potential for future success, Soligenix made the difficult decision to discontinue the late-stage development of HyBryte for CTCL. This announcement was formally communicated in the company’s second-quarter 2026 earnings release, confirming the termination of the program and marking the end of a significant investment in this particular therapeutic avenue.
Chronology of HyBryte Development and Discontinuation:
- Early Development: Soligenix develops HyBryte (SGX301), a topical therapy designed for CTCL, utilizing a light-activated hypericin formulation.
- Pre-clinical and Early Clinical Trials: The drug demonstrates promising results in earlier stages, leading to the initiation of Phase III trials.
- May 2026: Interim analysis of the Phase III FLASH2 trial (NCT06470451) indicates the trial is unlikely to meet its primary endpoints.
- Second Quarter 2026: Soligenix formally announces the termination of the HyBryte late-stage development program for CTCL, citing the trial’s interim results.
A Shift in Focus: Prioritizing Rare Disease and Vaccine Innovation
With the discontinuation of the HyBryte program in CTCL, Soligenix is strategically pivoting its resources and development efforts towards two key areas:
Advancing Dusquetide for Rare Inflammatory Conditions
The company will now place a primary focus on the progression of dusquetide, a pipeline candidate targeting rare inflammatory blood vessel conditions. Specifically, dusquetide is being developed for Behçet’s disease, a chronic, multisystem inflammatory disorder characterized by recurrent oral and genital ulcers, eye inflammation, skin lesions, and other systemic manifestations.
Dusquetide has already demonstrated a favorable safety and tolerability profile in a completed Phase II study (NCT06386744). This prior success provides a solid foundation for further clinical development, offering a potential new treatment option for patients suffering from the debilitating effects of Behçet’s disease, an area with significant unmet medical needs. The company’s leadership views dusquetide as a promising asset with the potential to address a critical gap in the treatment landscape for this rare inflammatory disorder.
Leveraging the ThermoVax Platform for Global Health
In parallel, Soligenix will intensify its efforts to secure commercial opportunities for its proprietary ThermoVax platform. This innovative technology is designed to facilitate the freeze-drying and ambient storage of protein and adjuvant-based vaccines. The primary benefit of ThermoVax is its potential to significantly reduce global reliance on complex and expensive cold-chain logistics, which are often a major barrier to vaccine distribution, particularly in low-resource settings.
The ThermoVax platform has the potential to revolutionize vaccine delivery by enabling vaccines to remain stable at room temperature for extended periods. This would allow for easier transportation, storage, and administration, thereby increasing accessibility to vital immunizations worldwide.
Soligenix is currently engaged in the early stages of developing vaccine candidates utilizing the ThermoVax platform for critical global health threats. This includes the development of vaccines against filoviral strains, such as Zaire and Sudan Ebolavirus, as well as a vaccine candidate for COVID-19. The ability to store these vaccines without refrigeration could be a game-changer in pandemic preparedness and response, as well as in the ongoing fight against endemic infectious diseases.
Supporting Data and Rationale for the Strategic Shift
The decision to reallocate resources is informed by a strategic assessment of the company’s pipeline and the broader market landscape. While HyBryte’s failure in CTCL is a disappointment, the company’s focus on dusquetide and ThermoVax aligns with emerging trends and critical global health priorities.
Dusquetide in Behçet’s Disease: Behçet’s disease affects approximately 1 in 10,000 people globally, with higher prevalence in certain regions, such as the Middle East and East Asia. Current treatment strategies often involve immunosuppressants and anti-inflammatory drugs, which can have significant side effects. The development of a targeted therapy like dusquetide, which has shown a favorable safety profile, represents a significant opportunity to address unmet needs and improve the quality of life for patients. The Phase II study data, demonstrating safety and tolerability, provides a strong basis for advancing dusquetide into later-stage clinical trials.
ThermoVax Platform: The global vaccine market is substantial and growing, driven by increased awareness of infectious disease threats and the need for rapid vaccine development and deployment. The challenges associated with maintaining the cold chain for traditional vaccines have been a persistent issue, leading to wastage and limiting access. The ThermoVax platform directly addresses this critical limitation. The market potential for thermostable vaccines is immense, particularly for routine immunizations in developing countries and for rapid response to emerging infectious disease outbreaks. The company’s early work on Ebolavirus and COVID-19 vaccines highlights the platform’s versatility and its potential to contribute to global health security.
Official Responses and Leadership Perspective
Christopher Schaber, President and CEO of Soligenix, articulated the company’s strategic direction in the wake of the HyBryte program’s termination. He stated, “While we are disappointed with the outcome of the HyBryte Phase III program, our team remains committed to advancing our innovative pipeline. We are now sharpening our focus on the development of dusquetide for rare inflammatory diseases, where we have seen promising early results, and on unlocking the significant commercial potential of our ThermoVax platform. We believe these strategic priorities are well-positioned to deliver substantial value to patients and shareholders.”
The company’s Q2 earnings release underscored this commitment, emphasizing the ongoing efforts to advance dusquetide and explore commercialization pathways for ThermoVax. This clear articulation of future direction aims to reassure investors and stakeholders about the company’s path forward.
Implications for the Pharmaceutical Landscape and Patient Care
The discontinuation of HyBryte highlights the inherent risks and challenges associated with drug development, particularly in complex diseases like CTCL. Despite rigorous scientific rationale and promising early-stage results, late-stage clinical trials can reveal limitations that ultimately lead to program termination. This outcome underscores the importance of continued investment in research and development across the pharmaceutical industry, as many promising therapies face similar hurdles.
For patients with CTCL, the failure of HyBryte means that current treatment options remain the standard of care. However, the news does not diminish the ongoing efforts in the field.
Advancements in Treating CTCL: A Broader Context
While HyBryte’s journey has concluded, the landscape for CTCL treatment continues to evolve, with several significant developments offering hope for patients:
- Adcetris (brentuximab vedotin): Developed by Seagen and commercialized by Pfizer (US/Canada) and Takeda (globally), Adcetris has emerged as a leading therapy for CTCL since its approval in 2017. In 2025, it generated $1.8 billion in revenue, highlighting its significant impact and market dominance in the indication.
- Lymphir (denileukin diftitox): In 2024, Citius Oncology received FDA approval for Lymphir, providing another treatment option for patients in the relapsed/refractory setting. The company has recently secured $36.5 million to accelerate its commercialization efforts, indicating a renewed push for this therapy.
Despite these advancements, significant unmet needs persist for CTCL patients. Delayed diagnosis remains a challenge, leading to more advanced disease at the time of presentation. Furthermore, the management of chronic itch, a common and distressing symptom of CTCL, continues to be a significant area of concern for patients and clinicians.
Looking ahead, researchers are exploring novel therapeutic avenues for CTCL. Kinase inhibitors and CAR-T therapies are being touted as the next frontier in treatment, offering the potential for more targeted and personalized approaches to combat this rare malignancy.
Impact of Soligenix’s Pivot:
Soligenix’s strategic shift to dusquetide and ThermoVax has several implications:
- For Rare Disease Patients: The accelerated focus on dusquetide offers a glimmer of hope for patients with Behçet’s disease, a condition with limited therapeutic options. If successful, dusquetide could significantly improve treatment outcomes and quality of life.
- For Global Health Security: The ThermoVax platform has the potential to be a transformative technology. Its ability to enable ambient-stable vaccines could dramatically improve vaccine accessibility in underserved regions and enhance preparedness for future pandemics. This focus aligns with a critical global health imperative.
- For the Pharmaceutical Industry: Soligenix’s decision underscores the dynamic nature of drug development. Companies must remain agile and willing to adapt their strategies based on scientific evidence and market opportunities. The success of dusquetide and ThermoVax could also pave the way for other companies to explore similar innovative vaccine stabilization technologies.
In conclusion, while the termination of the HyBryte program marks the end of a chapter for Soligenix, the company’s renewed focus on dusquetide for rare diseases and the promising ThermoVax vaccine platform positions it for future growth and impact. The strategic pivot demonstrates a commitment to addressing critical unmet medical needs and contributing to global health advancements. The pharmaceutical industry, like Soligenix, must continue to navigate the complexities of drug development, embracing innovation and adapting to scientific and market realities to bring life-changing therapies to patients worldwide.
About the Author
